Current trends in the efficacy and safety of Semaglutide in the glycemic control of diabetic patients: A literature review
DOI:
https://doi.org/10.33448/rsd-v13i7.46426Keywords:
Diabetes Mellitus; Efficacy; Medication.Abstract
The aim of this article is to examine current trends in the efficacy and safety of semaglutide in glycemic control among diabetic patients, seeking theoretical foundation from databases such as SciELO, LILACS, and PubMed. Twenty-eight articles were selected over the past three years, following defined inclusion and exclusion criteria, using the PRISMA methodology. Results indicated that semaglutide led to a significant reduction in short-term blood glucose levels, with lower hemoglobin A1c values compared to other treatments. The drug's safety was widely recognized, both in its subcutaneous and oral forms, although gastrointestinal side effects such as nausea and vomiting were frequently reported. A significant highlight was the potential reduction in adverse cardiovascular events associated with semaglutide use in diabetic patients. This review emphasizes semaglutide as an effective and safe therapeutic option for glycemic control in type 2 diabetic patients, with potential additional benefits in reducing cardiovascular complications.
References
Andersen et al. (2021). A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs, 81(9), 1003-1030.
Araki et al. (2022). Efficacy and safety of once-weekly semaglutide in japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: post-hoc analysis. Journal of diabetes investigation, 13(12), 1971-1980.
Araki et al. (2021). Efficacy and safety of oral semaglutide in japanese patients with type 2 diabetes: a post hoc subgroups analysis of the PIONEER 1,3, 4 and 8 trials. Diabetes, obesity & metabolism, 23(12), 2785-2794.
Aroda et al. (2020). Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1-5 trials. Diabetes, obesity & metabolism, 22(3), 303-314.
Berra et al. (2022). Real-world effectiveness of subcutaneous semaglutide in type 2 diabetes: a retrospective, cohort study (Sema-MiDiab01). Frontiers in endocrinology, 13, 109945.
Chun & Butts (2020). Long-acting GLP-1RAs: an overview of efficacy, safety and their role in type 2 diabetes management. JAAPA: official journal of the American Academy of Physician Assistants, 33, 3-18.
De Souza et al. (2020). Efficacy and safety of semaglutide for type 2 by race and ethnicity: a post hoc analysis of the SUSTAIN trials. J. clin. endocrinol. metab, 105(2).
Diretrizes Da Sociedade Brasileira De Diabetes, 2019-2020. Clanad: editora científica. 2019.
Fonseca K.P., & Rached C.D.A. (2019). Complicações Do Diabetes Mellitus. International Journal of Health Management, 1, 1-13.
Garcia de Lucas et al. (2022). Real-world use of once-weekly semaglutide in type 2 diabetes at an outpatient clinic in Spain. Front Endocrinol (Lausanne), 13, 995646-995646.
Hussain et al. (2020). Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular diabetology, 19(1), 156.
Janic et al. (2023). Efficacy, safety and patient satisfaction with oral semaglutide: first single-center clinical experience. The Journal of international medical research, 51(11), 3000605231211402.
Kobalava Z. D, & Kokhan E. V. (2020). [Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines. Kardiologiia, 60(9), 122-133.
Lingvay et al. (2020). Cardiovascular outcomes, safety and tolerability with oral semaglutide: insights for managed care. Am J Manag Care, 26(16), S344-S355.
Lopes et al. (2023). Gastrointestinal disorders potentially associated with semaglutide: an analysis from the Eudravigilance Database. Expert opinion on drug safety, 22(6), 455-461.
Marzullo et al. (2022). Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. J Endocrinol Invest, 45(8), 1587-1598.
Meier, J. J. (2021). Efficacy of semaglutide in a subcutaneous and an oral formulation. Frontiers in endocrinology, 12, 645617.
Menzen et al. (2023). Real-world use of once-weekly semaglutide in type 2 diabetes: results from semaglutide real-world evidence (SURE) Germany. Exp Clin Endocrinol Diabetes, 131(4), 205-215.
Ministério Da Saúde (2020). Plano de ações estratégicas para o enfrentamento das doenças crônicas e agravos não transmissíveis no Brasil 2021-2030. Secretaria de Vigilância em Saúde.
Nascimento, P. S. (2918). A célula Beta Pancreática na Diabetes. 2018. Dissertação (Mestrado Integrado em Medicina) - Faculdade de Medicina da Universidade de Coimbra, Portugal.
Okamoto et al. (2021). Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated of switched to semaglutide from other GLP-1 receptor agonists. Journal of diabetes and metabolic disorders, 20(2), 2121-2128.
Pereira, M. F. V., & Figueiredo, A. M. A. (2017). A importância do diagnóstico da Diabetes Mellitus tipos 1 e 2 na infância. SALUSVITA, 36(2), 601-614, 2017.
Pérez-Belmont. (2022). Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice. Frontiers in endocrinology, 13, 851035.
Pratley et al. (2021). Oral semaglutide reduces HbA(1c) and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER subgroups analyses. Diabetes therapy: research, treatment and education of diabetes and related disorders, 12(4), 1099-1116.
Rajamand et al. (2021). Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study. Primary care diabetes, 15(5), 871-878.
Shu et al. (2022). Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Frontiers in public health, 10, 996179.
Smits et al. (2021). Safety of semaglutide. Front Endocrinol (Lausanne), 12, 645563.
Seljas-Amigo et al. (2023). Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: a non-randomized multicenter study from the titration phase. Prim Care Diabetes, 17(4), 366-372.
Seljas-Amigo et al. (2022). Semaglutida versus agonistas GLP-1. Efectividad, seguridad y calidad de vida en pacientes con diabetes mellitus 2. Estudio SEVERAL. Farmacia Hospitalaria, 46(6), 372-379.
Shabutdinova, O. R. et al. (2023). Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP]. Probl Endokrinol (Mosk), 69(3), 68-82.
Souza, A. S., Oliveira, G. S., & Alves, L. H. (2021). A pesquisa bibliográfica: princípios e fundamentos. Cadernos da Fucamp, 20(43).
Wajid et al. (2023). Efficacy and tolerability of semaglutide in patients with type 2 diabetes mellitus: experience of a tertiary care hospital, Pakistan. Clinical medicine insights. Endocrinology and diabetes, 16, 11795514231213568.
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11), 989-1002.
Wright et al. (2020). Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate medicine, 132, 26-36.
Yale et al. (2021). Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab, 23(10), 2269-2278.
Yamada et al. (2020). Dose-response, efficacy and safety of oral semaglutide monotherapy in japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol, 8(5), 377-391.
Yamada et al. (2022). Effectiveness and safety of once-weekly semaglutide in japanese patients with type 2 diabetes in treatment intensification: a retrospective observational single-center study. Diabetes therapy: research, treatment and education of diabetes and related disorders, 13(10), 1779-1788.
Yamada et al. (2023). Retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in japanese clinical settings. Journal of cardiovascular development and disease, 10(4).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alyne Werner Mota Pereira; Júlia Andrade Pereira; Stefany Miareli Ferreira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
